Tissue Regenix Group PLC Distribution agreement for OrthoPure(R) XT (0887E)
March 09 2022 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 0887E
Tissue Regenix Group PLC
09 March 2022
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Exclusive distribution agreement for OrthoPure (R) XT with
Geistlich Biomaterials Italia
Tissue Regenix Group (AIM:TRX), the regenerative medical devices
company, announces that it has signed an exclusive distribution
agreement with Geistlich Biomaterials Italia ("Geistlich"), a
subsidiary company of Geistlich Pharma AG, a global company with a
focus on regenerative products for bone, cartilage and tissue, for
the distribution of OrthoPure XT in Italy.
The OrthoPure XT decellularised xenograft ligament utilises
Tissue Regenix's patented dCell(R) technology and is the only
available non-human biologic graft indicated for certain ligament
reconstruction procedures. OrthoPure XT was commercially launched
in December 2020 after being awarded a CE Mark for revision of
anterior cruciate ligament (ACL) reconstruction procedures and
reconstruction of other knee ligaments, including multiligament and
primary procedures when the autograft is unacceptable. The
biocompatible implant provides a biomechanically appropriate tissue
scaffold for cellular repopulation and eventual regeneration.
The multiyear distribution agreement covers Italy currently but
also has the potential for extension to wider geographies. As part
of the agreement, Geistlich has also committed to advance the
clinical science surrounding OrthoPure XT which will be conducted
at some of the leading institutions by clinicians in Italy.
Filippo Baldini, National Sales Manager for Geistlich
Biomaterials Italia, commented : "Geistlich is excited to bring
this new technology to the Italian market and serve the patient's
needs with this innovative solution."
Prof. Stefano Zaffagnini of the Istituto Ortopedico Rizzoli in
Bologna, Italy stated: "Our centre has demonstrated an interest in
xenograft options for our patients and the OrthoPure XT has the
potential to address needs in knee surgeries."
Daniel Lee, Chief Executive Officer of Tissue Regenix,
commented: "We are pleased to partner with Geistlich for our
commercial efforts in Italy. Geistlich is a leader in regenerative
products, so our commitments are aligned in delivering innovative
products to advance patient care. We are excited to work with them
to build the clinical experience with OrthoPure XT and introduce
this transformative product to the Italian medical community."
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by
the Group to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK
domestic law by virtue of the European Union (Withdrawal) Act 2018
('MAR'). Upon the publication of this announcement via Regulatory
Information Service ('RIS'), this inside information is now
considered to be in the public domain.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600
and Broker)
Ben Maddison / Nick Harland
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs such as in sports
medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, dental, and ophthalmological surgical procedures.
About Geistlich Pharma AG and Geistlich Biomaterials Italia
s.r.l.
Geistlich Pharma AG develops, manufactures and markets medical
devices for restoring bone, cartilage and soft tissue as well as
drugs. The Swiss company Geistlich Pharma is part of the Geistlich
Group and has been family-owned since 1851. Geistlich Pharma has a
worldwide sales and distribution network with twelve subsidiary
companies and more than 70 distributors. Geistlich Biomaterials
Italia s.r.l. is a subsidiary company of Geistlich Pharma AG and
markets products in regenerative dentistry, in orthopaedic and
sports medicine within the territory of Italy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRJPMFTMTAMBPT
(END) Dow Jones Newswires
March 09, 2022 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024